Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized adjunctive EQU-101 for uncontrolled focal epilepsy
MOH_2022-09-05_011902Phase 2Completed
- Sponsor
- Equilibre Biopharmaceuticals
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of equ-001 in Focal Onset Epilepsy (3 arms), sponsored by Equilibre Biopharmaceuticals. Primary endpoint: Median percent change in 4-week seizure frequency. Started Jun 2022; status: completed.
02
Drugs
equ-001
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on MOH_2022-09-05_011902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-05_011902.